MEF-2 isoforms' (A-D) roles in development and tumorigenesis

Kiran Madugula, Ria Mulherkar, Zafar K. Khan, De Gaulle I. Chigbu, Dip Patel, Edward W. Harhaj, Pooja Jain

Research output: Contribution to journalReview article

Abstract

Myocyte enhancer factor (MEF)-2 plays a critical role in proliferation, differentiation, and development of various cell types in a tissue specific manner. Four isoforms of MEF-2 (A-D) differentially participate in controlling the cell fate during the developmental phases of cardiac, muscle, vascular, immune and skeletal systems. Through their associations with various cellular factors MEF-2 isoforms can trigger alterations in complex protein networks and modulate various stages of cellular differentiation, proliferation, survival and apoptosis. The role of the MEF-2 family of transcription factors in the development has been investigated in various cell types, and the evolving alterations in this family of transcription factors have resulted in a diverse and wide spectrum of disease phenotypes, ranging from cancer to infection. This review provides a comprehensive account on MEF-2 isoforms (A-D) from their respective localization, signaling, role in development and tumorigenesis as well as their association with histone deacetylases (HDACs), which can be exploited for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)2755-2787
Number of pages33
JournalOncotarget
Volume10
Issue number28
DOIs
StatePublished - Apr 12 2019

Fingerprint

MEF2 Transcription Factors
Protein Isoforms
Carcinogenesis
Transcription Factors
Histone Deacetylases
Blood Vessels
Immune System
Myocardium
Cell Proliferation
Apoptosis
Phenotype
Infection
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Madugula, K., Mulherkar, R., Khan, Z. K., Chigbu, D. G. I., Patel, D., Harhaj, E. W., & Jain, P. (2019). MEF-2 isoforms' (A-D) roles in development and tumorigenesis. Oncotarget, 10(28), 2755-2787. https://doi.org/10.18632/oncotarget.26763
Madugula, Kiran ; Mulherkar, Ria ; Khan, Zafar K. ; Chigbu, De Gaulle I. ; Patel, Dip ; Harhaj, Edward W. ; Jain, Pooja. / MEF-2 isoforms' (A-D) roles in development and tumorigenesis. In: Oncotarget. 2019 ; Vol. 10, No. 28. pp. 2755-2787.
@article{7b96f9e9dac848eca05f403f4b6a14a8,
title = "MEF-2 isoforms' (A-D) roles in development and tumorigenesis",
abstract = "Myocyte enhancer factor (MEF)-2 plays a critical role in proliferation, differentiation, and development of various cell types in a tissue specific manner. Four isoforms of MEF-2 (A-D) differentially participate in controlling the cell fate during the developmental phases of cardiac, muscle, vascular, immune and skeletal systems. Through their associations with various cellular factors MEF-2 isoforms can trigger alterations in complex protein networks and modulate various stages of cellular differentiation, proliferation, survival and apoptosis. The role of the MEF-2 family of transcription factors in the development has been investigated in various cell types, and the evolving alterations in this family of transcription factors have resulted in a diverse and wide spectrum of disease phenotypes, ranging from cancer to infection. This review provides a comprehensive account on MEF-2 isoforms (A-D) from their respective localization, signaling, role in development and tumorigenesis as well as their association with histone deacetylases (HDACs), which can be exploited for therapeutic intervention.",
author = "Kiran Madugula and Ria Mulherkar and Khan, {Zafar K.} and Chigbu, {De Gaulle I.} and Dip Patel and Harhaj, {Edward W.} and Pooja Jain",
year = "2019",
month = "4",
day = "12",
doi = "10.18632/oncotarget.26763",
language = "English (US)",
volume = "10",
pages = "2755--2787",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "28",

}

Madugula, K, Mulherkar, R, Khan, ZK, Chigbu, DGI, Patel, D, Harhaj, EW & Jain, P 2019, 'MEF-2 isoforms' (A-D) roles in development and tumorigenesis', Oncotarget, vol. 10, no. 28, pp. 2755-2787. https://doi.org/10.18632/oncotarget.26763

MEF-2 isoforms' (A-D) roles in development and tumorigenesis. / Madugula, Kiran; Mulherkar, Ria; Khan, Zafar K.; Chigbu, De Gaulle I.; Patel, Dip; Harhaj, Edward W.; Jain, Pooja.

In: Oncotarget, Vol. 10, No. 28, 12.04.2019, p. 2755-2787.

Research output: Contribution to journalReview article

TY - JOUR

T1 - MEF-2 isoforms' (A-D) roles in development and tumorigenesis

AU - Madugula, Kiran

AU - Mulherkar, Ria

AU - Khan, Zafar K.

AU - Chigbu, De Gaulle I.

AU - Patel, Dip

AU - Harhaj, Edward W.

AU - Jain, Pooja

PY - 2019/4/12

Y1 - 2019/4/12

N2 - Myocyte enhancer factor (MEF)-2 plays a critical role in proliferation, differentiation, and development of various cell types in a tissue specific manner. Four isoforms of MEF-2 (A-D) differentially participate in controlling the cell fate during the developmental phases of cardiac, muscle, vascular, immune and skeletal systems. Through their associations with various cellular factors MEF-2 isoforms can trigger alterations in complex protein networks and modulate various stages of cellular differentiation, proliferation, survival and apoptosis. The role of the MEF-2 family of transcription factors in the development has been investigated in various cell types, and the evolving alterations in this family of transcription factors have resulted in a diverse and wide spectrum of disease phenotypes, ranging from cancer to infection. This review provides a comprehensive account on MEF-2 isoforms (A-D) from their respective localization, signaling, role in development and tumorigenesis as well as their association with histone deacetylases (HDACs), which can be exploited for therapeutic intervention.

AB - Myocyte enhancer factor (MEF)-2 plays a critical role in proliferation, differentiation, and development of various cell types in a tissue specific manner. Four isoforms of MEF-2 (A-D) differentially participate in controlling the cell fate during the developmental phases of cardiac, muscle, vascular, immune and skeletal systems. Through their associations with various cellular factors MEF-2 isoforms can trigger alterations in complex protein networks and modulate various stages of cellular differentiation, proliferation, survival and apoptosis. The role of the MEF-2 family of transcription factors in the development has been investigated in various cell types, and the evolving alterations in this family of transcription factors have resulted in a diverse and wide spectrum of disease phenotypes, ranging from cancer to infection. This review provides a comprehensive account on MEF-2 isoforms (A-D) from their respective localization, signaling, role in development and tumorigenesis as well as their association with histone deacetylases (HDACs), which can be exploited for therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=85064978539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064978539&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.26763

DO - 10.18632/oncotarget.26763

M3 - Review article

C2 - 31105874

AN - SCOPUS:85064978539

VL - 10

SP - 2755

EP - 2787

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -

Madugula K, Mulherkar R, Khan ZK, Chigbu DGI, Patel D, Harhaj EW et al. MEF-2 isoforms' (A-D) roles in development and tumorigenesis. Oncotarget. 2019 Apr 12;10(28):2755-2787. https://doi.org/10.18632/oncotarget.26763